Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro Rocha

Showing results (121-130 of 134) with videos related to

Pageof 14
Sort By:
Cancer Immunology, Immunotherapy : CII|January 8, 2021
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Stroke|July 25, 2024
Plasma Brain-Derived Tau in Prognosis of Large Vessel Occlusion Ischemic StrokeRicardo Varela, Fernando Gonzalez-Ortiz, Alexandre Dias, et al.
Cell Reports. Medicine|June 21, 2025
MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancerRaúl Del Rey-Vergara, Miguel Alejandro Galindo-Campos, Pedro Rocha, et al.
British Journal of Cancer|April 20, 2022
Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancerBingnan Zhang, C Allison Stewart, Qi Wang, et al.
NPJ Precision Oncology|November 18, 2024
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasmsAlejandra G Serrano, Pedro Rocha, Cibelle Freitas Lima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant ChemoimmunotherapyMarta Casarrubios, Alberto Cruz-Bermúdez, Ernest Nadal, et al.
Oncoimmunology|February 24, 2025
Molecular and immunological features associated with long-term benefits in metastatic NSCLC patients undergoing immune checkpoint blockadePedro Rocha, Rafael Bach, Laura Masfarré, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 14, 2023
Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung CancerAlejandro Francisco-Cruz, Pedro Rocha, Alexandre Reuben, et al.
Cancers|December 11, 2025
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung CancerHui Li, Lingzhi Hong, Pedro Rocha, et al.
Cancer Cell|January 26, 2024
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypesSimon Heeke, Carl M Gay, Marcos R Estecio, et al.
Pageof 14

Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
Cancer Immunology, Immunotherapy : CII|January 8, 2021
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Stroke|July 25, 2024
Plasma Brain-Derived Tau in Prognosis of Large Vessel Occlusion Ischemic StrokeRicardo Varela, Fernando Gonzalez-Ortiz, Alexandre Dias, et al.
Cell Reports. Medicine|June 21, 2025
MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancerRaúl Del Rey-Vergara, Miguel Alejandro Galindo-Campos, Pedro Rocha, et al.
British Journal of Cancer|April 20, 2022
Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancerBingnan Zhang, C Allison Stewart, Qi Wang, et al.
NPJ Precision Oncology|November 18, 2024
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasmsAlejandra G Serrano, Pedro Rocha, Cibelle Freitas Lima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant ChemoimmunotherapyMarta Casarrubios, Alberto Cruz-Bermúdez, Ernest Nadal, et al.
Oncoimmunology|February 24, 2025
Molecular and immunological features associated with long-term benefits in metastatic NSCLC patients undergoing immune checkpoint blockadePedro Rocha, Rafael Bach, Laura Masfarré, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 14, 2023
Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung CancerAlejandro Francisco-Cruz, Pedro Rocha, Alexandre Reuben, et al.
Cancers|December 11, 2025
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung CancerHui Li, Lingzhi Hong, Pedro Rocha, et al.
Cancer Cell|January 26, 2024
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypesSimon Heeke, Carl M Gay, Marcos R Estecio, et al.
Pageof 14